Argenx announced a tender offer to acquire Forte Biosciences, the San Diego immunology developer, in a deal valued at approximately $200 million based on current share prices. The move consolidates two overlapping dermatology pipelines ahead of what market participants expect will be a competitive regulatory environment in atopic dermatitis treatments through 2025.

Forte holds FB-102, a biologic targeting cytokine signaling pathways in moderate-to-severe atopic dermatitis, currently in Phase 2b trials with topline data expected in Q3 2025. Argenx operates efgartigimod, a neonatal Fc receptor antagonist approved in generalized myasthenia gravis and under investigation for chronic inflammatory demyelinating polyneuropathy. The company has publicly disclosed its intent to expand into dermatology indications, and Forte's clinical infrastructure provides immediate patient-access networks and regulatory groundwork in a high-incidence therapeutic area.

The tender offer structure bypasses shareholder-vote timelines, allowing argenx to move faster than a traditional merger would permit. This matters because three other atopic dermatitis biologics are in late-stage trials with regulatory submissions expected before year-end 2025. Forte's existing relationships with 14 North American dermatology centers and pre-negotiated manufacturing partnerships mean argenx acquires operational momentum, not just intellectual property. The Belgian firm has €1.8 billion in cash as of its last quarterly filing, making this acquisition financially immaterial to its balance sheet but strategically weighted.

Market intelligence suggests argenx is positioning for a dual-pathway approval strategy: efgartigimod for systemic autoimmune dermatoses and FB-102 for localized inflammatory skin conditions. This separation allows the company to avoid direct competition between its own assets while capturing different payer reimbursement channels. The atopic dermatitis market is projected to exceed $14 billion annually by 2028, driven by biologic uptake in pediatric populations where topical corticosteroids remain the standard but unsatisfactory care.

Operators should track three specific catalysts. First, the tender offer's acceptance threshold and premium-to-market pricing, which will clarify argenx's acquisition appetite for other dermatology assets. Second, FB-102's Phase 2b data release in Q3 2025, which will determine whether argenx accelerates or shelves the program. Third, any revised guidance on argenx's dermatology commercial build-out, particularly hiring announcements in medical affairs and patient-access teams, which would signal commitment beyond this single transaction.

The deal closes a 26-month period during which Forte's stock traded below $2 per share despite advancing its lead program through clinical milestones. Argenx is paying for late-stage proximity, not proven efficacy, a calculated bet that dermatology reimbursement tailwinds justify pre-approval risk.